In a new program from CancerNetwork®, experts discuss key data updates in multiple myeloma from ASCO 2022 based on real-world evidence and how they can be applied into clinical practice.
EP. 1: Frontline Treatment Options for Transplant-Ineligible Newly Diagnosed Multiple Myeloma
Dr Luciano Costa provides an overview of the currently available treatment options for patients with transplant-ineligible, newly diagnosed multiple myeloma.
EP. 2: Comparison of Results from the MAIA and SWOG0777 Studies
Rafael Fonseca, MD, describes key data from the MAIA and SWOG 0777 studies investigating triplet regimens in multiple myeloma treatment, and how the results compare.
EP. 3: Triplet vs Doublet Induction Therapy for Transplant-Ineligible MM and Role of Real-World Evidence
A key opinion leader explains whether doublet regimens still have a place in transplant-ineligible multiple myeloma treatment.
EP. 4: Treatment Decision-Making Based on Real-World Data in Transplant-Ineligible NDMM
Dr Rafael Fonesca illustrates how he selects therapies for patients with transplant-ineligible multiple myeloma based on real-world evidence.
EP. 5: Maintenance Therapy in Transplant-Ineligible Multiple Myeloma
Luciano Costa, MD, PhD, discusses his maintenance therapy strategies for patients with transplant-ineligible multiple myeloma.
EP. 6: Determining Treatment Duration for Transplant-Ineligible Multiple Myeloma
An expert describes how he determines treatment duration and discontinuation for transplant-ineligible multiple myeloma in his clinical practice.
EP. 7: Unmet Needs of Transplant-Ineligible Multiple Myeloma
A look at some of the unmet needs in transplant-ineligible multiple myeloma, particularly within the unfit patient population.
EP. 8: Racial Disparities in the Treatment of Multiple Myeloma Patients
Drs Costa and Fonesca close out their discussion by highlighting the endemic racial disparities in multiple myeloma treatment.
EP. 9: Comparing Combination Treatment Regimens in Transplant-Eligible NDMM
Matthew James Pianko, MD, provides an overview of the recently updated data from the GRIFFIN trial and the role of quadruplet versus triplet regimens in the treatment landscape of transplant-eligible newly diagnosed multiple myeloma.
EP. 10: Is There a Role for MRD-Response Adapted Therapy in Transplant-Eligible NDMM?
Dr Ajay Nooka describes key data from the uniquely-designed MASTER trial investigating daratumumab in combination with carfilzomib, lenalidomide and dexamethasone (Dara-KRd) versus KRd in transplant-eligible newly diagnosed multiple myeloma.
EP. 11: The GMMG HD7 Trial of Isa-VRd vs VRd in Transplant-Eligible NDMM
An expert reviews data from the ongoing GMMG HD7 (German) trial investigating isatuximab in combination with bortezomib, lenalidomide and dexamethasone (Isa-VRd) versus VRd in the treatment of transplant-eligible newly diagnosed multiple myeloma.
EP. 12: Treatment Decision-Making Based on Clinical Trial Data in Transplant-Eligible NDMM
Ajay Nooka, MD, explains how he selects treatment regimens for patients with newly diagnosed transplant-eligible multiple myeloma in his clinical practice.
EP. 13: Treatment Decision-Making Based on Real-World Data in Transplant-Eligible NDMM
An oncologist muses on the potential of real-world data in evaluating the use of a quadruplet regimen for newly diagnosed transplant-eligible multiple myeloma.
EP. 14: Measuring Treatment Response in Transplant-Eligible NDMM after Induction Therapy
Drs Nooka and Pianko discuss how they measure a successful treatment response in patients with transplant-eligible multiple myeloma after induction therapy.
EP. 15: Recap: Recent Advances in Multiple Myeloma: Applying Real-world Evidence to Clinical Practice
Following the 2022 American Society of Clinical Oncology Annual Meeting, experts in multiple myeloma discuss real-world evidence as it relates to the present-day treatment of patients.
EP. 16: Determining Treatment Duration for Transplant-Eligible NDMM
Dr Matthew James Pianko details how he determines treatment duration and discontinuation for transplant-eligible multiple myeloma.
EP. 17: Racial Disparities in Presentation, Diagnosis, and Treatment of MM
Closing out the program, Dr Ajay Nooka comments on the structural and biological disparities of care in multiple myeloma between Black and Caucasian patients, including age of presentation, delay of diagnosis and treatment, access to treatment options, and treatment response.
EP. 18: Unmet Needs and Future Perspectives in Transplant-Eligible NDMM
A look at some of the unmet needs in transplant-eligible multiple myeloma, particularly within the high-risk patient population.
EP. 19: Characterization and Management of High-Risk Patients with MM
Ajay Nooka, MD, and Matthew James Pianko, MD, discuss how they risk stratify patients with transplant-eligible multiple myeloma and the corresponding treatment approaches.
2 Clarke Drive Cranbury, NJ 08512